Telomere length shortening in non-Hodgkin's lymphoma patients undergoing chemotherapy

We investigated telomere length changes in patients with non-Hodgkin's lymphoma (NHL) receiving conventional-dose chemotherapy. Using Southern blot analysis, telomere length was measured in peripheral blood mononuclear cells from five NHL patients at diagnosis, 15 NHL patients after chemotherap...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2003-08, Vol.82 (8), p.492-495
Main Authors: LEE, J.-J, NAM, C.-E, CHO, S.-H, PARK, K.-S, CHUNG, I.-J, KIM, H.-J
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Protocols
Biological and medical sciences
Blotting, Southern
Case-Control Studies
Chemotherapy
Cyclophosphamide
Doxorubicin
Female
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - genetics
Male
Medical sciences
Monocytes
Prednisolone
Stem cells
Telomere - genetics
Time Factors
Vincristine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated telomere length changes in patients with non-Hodgkin's lymphoma (NHL) receiving conventional-dose chemotherapy. Using Southern blot analysis, telomere length was measured in peripheral blood mononuclear cells from five NHL patients at diagnosis, 15 NHL patients after chemotherapy, and 39 healthy controls. Compared with age-matched putative normal controls, telomeres were significantly shorter in NHL patients at diagnosis. Mean telomere length was shorter after chemotherapy than before chemotherapy and was shorter after chemotherapy than in age-matched putative healthy controls. There was no correlation between the extent of telomere shortening and time elapsed after chemotherapy. These findings suggest that in NHL patients hematopoietic stem cells lose telomere length during the recovery period from bone marrow suppression after conventional-dose chemotherapy.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-003-0691-4